Catalog Peptides Market Insights, Leading Players and Growth Forecast Report 2024

Isabella Turner

Development of new drug production technologies and peptides will help the catalog peptides market to advance at a CAGR of 5.8% during 2019–2024. For example, a surge in research activities to understand the efficient expression of difficult-to-express and new proteins, through cell line and protein engineering, is a step toward upcoming drug discoveries. Owing to the escalating researches focusing on the unmet requirements for chronic ailments, such as cancer, respiratory disorders, and ischemic heart disease, government organizations are investing hefty amounts on research activities to develop new cost-effective drugs.

Receive Sample Copy of this Report:

According to P&S Intelligence, the market was valued at $238.4 million in 2018 and it is expected to reach $332.1 million by 2024. This can be primarily ascribed to the researches in recombinant deoxyribonucleic acid (DNA) technology. This technology is viewed as an effective molecular biology technique for the production of biopharmaceuticals. This technology can produce a high volume of desired and purified recombinant proteins that may increase its application in the diagnosis and treatment of diseases and industrial processes.

Make an Enquiry before Purchase:

Moreover, development of advanced platforms for peptide synthesis by private companies has led to the increased production of catalog peptides. For example, New England Peptide Inc. (NEP) utilizes its PepTrend system to synthesize and design peptides. The company also uses its proprietary peptide array platform to synthesize 96 types of peptides at a rapid pace and in a cost-effective manner. These technological advancements have enhanced the production capability of companies for the creation of advanced peptides that are used for research and antibody development purposes.

The catalog peptides market offers calcitonin gene-related, cyclic, caspase related, adrenomedullin, tau, amyloid, G-protein-coupled receptor (GPCR), anti-microbial, cosmetic, and amylin peptides. Among these, cyclic peptide is the most widely used peptide, as it possesses diverse biological activities like immunosuppressive, anti-tumor, and antibacterial. All these peptides find wide applications in academic and research institutes, contract manufacturing organizations (CMOs) and contract research organizations (CROs), and pharmaceutical and biotechnology companies. Of the various end users, the pharmaceutical and biotechnology companies consume the highest volume of peptides to manufacture drugs and evaluate the application of peptides as therapeutics.

In recent years, market players have increased their focus on geographical expansions, product launches, and acquisitions to consolidate their position. For example, Aviva Systems Biology Corporation (ASB) completed the acquisition of GenWay Biotech Incorporated, in February 2017, to widen its product portfolio by including GenWay’s enzyme-linked immunosorbent assay (ELISA), antibodies, and proteins. Through this acquisition, ASB aims to become a key provider of proteomic solutions in the market. Other companies adopting these strategic measures include PolyPeptide Group, Biomatik Corporation, CPC Scientific Inc., LifeTein LLC, AAPPTec LLC, New England Peptide Inc., and AnaSpec Inc.

Globally, North America utilized the highest volume of catalog peptides, due to the strong presence of established players, rapid advancements in peptide production technologies, and huge investments in research and development (R&D) of peptides and related technologies. The U.S. will consume the larger quantity of catalog peptides in the coming years, owing to the burgeoning demand for peptide-based therapeutics to treat chronic disorders, well-established R&D infrastructure, and an ample number of Food and Drug Administration (FDA) products in the nation. Thus, the escalation in R&D activities and the rise in funding from the private and public organizations will fuel the usage of catalog peptides in the coming years.

Leave a Comment